# Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

> **NCT01991561** · PHASE2 · COMPLETED · sponsor: **Medicago** · enrollment: 390 (actual)

## Conditions studied

- Virus Diseases
- RNA Virus Infections
- Respiratory Tract Diseases
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** Low dose of H5 VLP vaccine + Alhydrogel
- **BIOLOGICAL:** Med dose of H5 VLP vaccine + Alhydrogel
- **BIOLOGICAL:** High dose of H5 VLP vaccine + Alhydrogel
- **BIOLOGICAL:** Low dose of H5 VLP vaccine + GLA-SE
- **BIOLOGICAL:** High dose of H5 VLP vaccine + GLA-SE
- **BIOLOGICAL:** Placebo comparator: Placebo

## Key facts

- **NCT ID:** NCT01991561
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-07
- **Final completion:** 2014-11
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01991561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01991561, "Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01991561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*